Biological Evaluation of Cleavable Linkers in Exatecan-Based Antibody-Drug Conjugates: A Comparative Study of DXd and Exo-Linker Platforms
Preprint
- 23 December 2024
- preprint
- Published by American Chemical Society (ACS) in ChemRxiv
Abstract
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxicity of potent drug payloads. This study presents the development and evaluation of a novel exolinker designed to enhance ADC stability and pharmacokinetics by addressing the limitations associated with traditional cleavable linkers. Using trastuzumab conjugated with a payload linker consisting of an exo-linker and exo-EVC-Exatecan (APL-1082), we examined key parameters, including in vivo efficacy and pharmacokinetic profiles in rat models, to directly compare it with the clinically validated trastuzumab-deruxtecan (T-DXd, Enhertu). Our Exo-linker ADC demonstrated superior stability and maintained drug-to-antibody ratios (DAR) with reduced aggregation and hydrophobicity compared to T-DXd, suggesting an improved pharmacokinetic profile. Additionally, combining the Exo-linker with AJICAP site-specific conjugation technology enabled the production of high-DAR ADCs, achieving a DAR of 10 with promising homogeneity and physicochemical properties. Collectively, these findings underscore the potential of the exo-linker as a versatile platform for next-generation ADCs, offering enhanced stability, efficacy, and expanded therapeutic possibilities.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody–Drug ConjugatesJournal of Medicinal Chemistry, 2024
- Novel antibody-drug conjugates based on DXd-ADC technologyBioorganic Chemistry, 2024
- Biological Evaluation of Antibody-Drug Conjugates Produced by Tag-Free Lipoate Ligase A ModificationBiochemistry, 2024
- AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody–Drug Conjugate ProductionBioconjugate Chemistry, 2023
- Tag‐Free Enzymatic Modification for Antibody−Drug Conjugate ProductionChemistrySelect, 2022
- Lipoate-acid ligase a modification of native antibody: Synthesis and conjugation site analysisBioorganic & Medicinal Chemistry Letters, 2021
- Linker Architectures as Steric Auxiliaries for Altering Enzyme-Mediated Payload Release from BioconjugatesBioconjugate Chemistry, 2021
- Chromatographic analysis of site-specific antibody-drug conjugates produced by AJICAP first-generation technology using a recombinant FcγIIIa receptor-ligand affinity columnJournal of Chromatography B, 2021
- Comparison of Analytical Methods for Antibody–Drug Conjugates Produced by Chemical Site-Specific Conjugation: First-Generation AJICAPAnalytical Chemistry, 2019
- Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid ConjugatesBioconjugate Chemistry, 2017